Intravenous belimumab plus SOC vs placebo plus SOC was not linked to an increased risk for infection among patients with SLE.

A team studied the differences between monogenic and nonmonogenic lupus nephritis and the predictors of end-stage kidney disease. Monogenic lupus nephritis is distinct from non-monogenic disease with ...

BackgroundLupus erythematosus panniculitis (LEP) is a rare variant of cutaneous lupus erythematosus that typically presents as indurated nodules or plaques. Calcinosis cutis (CC) is a potential ...

Bullous systemic lupus erythematosus (BSLE) is a rare type of lupus that causes blisters. Learn about the symptoms, causes, treatment options, and more.

Lupus affects different people in different ways, and skin problems like rashes or sores re common. In a new study, people with systemic lupus erythematosus (SLE) were found to be at higher risk for ...

A RECENT retrospective study sheds light on the epidemiology of isolated Cutaneous Lupus Erythematosus (CLE) within the multiethnic population of Reunion Island, France. Conducted across public ...

Discoid lupus erythematosus: This is the most common type of cutaneous lupus. It causes a rash of disc-shaped patches that are raised, thick, and scaly. As the patches fade, dark spots and permanent ...

Kezar Life Sciences is discontinuing a lupus program after four patient deaths occurred during a Phase IIb trial and will focus on developing the same drug in autoimmune hepatitis. Earlier this month, ...

Tumid lupus is a rare form of cutaneous lupus erythematosus. It causes a person to develop smooth, nonscarring pimples on their skin. These pimples are often pink-to-violet in color.

lupus profundus (panniculitis), which causes firm, deep nodules chilblain lupus erythematosus, which causes lesions on the fingers and toes often triggered by cold temperatures ...

Type 1 interferons (IFNs) play a central role in the development and disease course of systemic lupus erythematosus (SLE). In a new study, researchers explored SLE disease activity and type I ...

Cutaneous Lupus Erythematosus Disease Area and Severity Index–Activity (CLASI-A) was assessed at baseline and post-treatment visits.Results Patient 1: Anifrolumab effectively treated refractory ...